Patents Examined by Anoop K. Singh
  • Patent number: 10799461
    Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: October 13, 2020
    Assignee: ENGENEIC MOLECULAR DELIVERY PTY LTD
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 10779519
    Abstract: The present invention is directed to a method of assessing in vivo human glial cell response to pathogenic infection that involves providing a non-human mammal either with at least 30% of its glial cells in its corpus callosum being human glial cells and/or with at least 5% of its glial cells its brain and brain stem white matter being human glial cells, subjecting the non-human mammal to pathogenic infection and assessing the in vivo human glial cell response to pathogenic infection. A method of identifying therapeutic agents for the pathogenic infection as well as forms of the non-human mammal having a pathogenic brain infection are also disclosed.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: September 22, 2020
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Steven A. Goldman, Martha Windrem
  • Patent number: 10767161
    Abstract: A hierarchy of endothelial colony forming cells (EPCs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential—endothelial colony forming cell (HPP-ECFC) was isolated and characterized. Single cell assays were developed that test the proliferative and clonogenic potential of endothelial cells derived from cord blood, or from HUVECs and HAECs. EPCs were found to reside in vessel walls. Use of a feeder layer of cells derived from high proliferative potential-endothelial colony forming cells (HPP-ECPCS) from human umbilical cord blood, stimulates growth and survival of repopulating hematopoietic stem and progenitor cells. Stimulation of growth and survival was determined by increased numbers of progenitor cells in in vitro cultures and increased levels of human cell engraftment in the NOD/SCID immunodeficient mouse transplant system.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: September 8, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Mervin C. Yoder, David A. Ingram
  • Patent number: 10759841
    Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: September 1, 2020
    Assignee: Helixmith Co., Ltd.
    Inventors: Jong Mook Kim, Jae Gyun Jeong
  • Patent number: 10752915
    Abstract: In one aspect, the present invention provides an intron-modified capsid expression cassette useful for generating adeno-associated virus (AAV) vector particles. In another aspect, the present invention provides a method of reducing the immune response in a mammalian subject undergoing treatment with an AAV vector.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: August 25, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Arthur Dusty Miller, Christine L. Halbert, Michael J. Metzger
  • Patent number: 10751399
    Abstract: An isolated nucleic acid that contains a nucleotide sequence that encodes the polypeptide of SEQ ID NO: 3. The polypeptide of SEQ ID NO: 3 specifically binds to stage-specific embryonic antigen 4 (SSEA4). Also disclosed is a recombinant cell comprising the isolated nucleic acid described above, a viral vector containing the above isolated nucleic acid, and an isolated polypeptide including the sequence of SEQ ID NO: 3. Provided as well is a chimeric antigen receptor (CAR) that includes a single chain Fv having the sequence of SEQ ID NO: 3 and specifically binding to SSEA4. Moreover, a method is disclosed for treating a tumor by transducing in vitro the T cells of a subject having a tumor expressing SSEA4 with a vector that encodes the CAR, expanding the transduced T cells, and infusing the expanded transduced T cells into the subject, whereby an anti-tumor T cell response is raised.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 25, 2020
    Assignee: CHO Pharma USA, Inc.
    Inventor: Lan Bo Chen
  • Patent number: 10745668
    Abstract: Described herein are methods for enhancing the nuclear reprogramming of somatic cells to become induced pluripotent stem cells. In particular, the methods disclosed herein involve the use of damage-associated molecular pattern molecules (DAMP). In certain embodiments the DAMPs are aluminum compositions such as aluminum hydroxide. Such DAMPs have unexpectedly and surprisingly been found to enhance the nuclear reprogramming efficiency of the reprogramming factors commonly used to induce somatic cells to become induced pluripotent stem cells. Accordingly, this disclosure describes methods of nuclear reprogramming as well as cells obtained from such methods along with therapeutic methods for using such cells for the treatment of disease amendable to treatment by stem cell therapy; as well as kits for such uses.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 18, 2020
    Assignee: LONZA LTD
    Inventors: Patrick Walsh, Thomas Fellner
  • Patent number: 10731134
    Abstract: It is intended to provide a cancer stem cell and a method for preparing the same. The present invention provides a method for preparing a pluripotent cancer stem cell, comprising transferring Oct3/4, Sox2, Klf4, and c-Myc genes to an immortalized epithelial cell. The present invention also provides a pluripotent cancer stem cell as prepared by the above method.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: August 4, 2020
    Assignee: Public University Corporation Yokohama City University
    Inventors: Akihide Ryo, Mayuko Nishi
  • Patent number: 10709120
    Abstract: A nonhuman animal cancer model is described. The animal model includes an animal of the genus Peromyscus and xenograft cancer cells implanted in the animal. Methods for utilizing the animal model can include evaluation of growth and development of cancer cells as well as evaluation of known and potential cancer treatment therapies. The animal model can be utilized to examine the efficacy of an anticancer therapy at the preclinical stage, can be utilized to screen potential cancer treatments in an individualized cancer treatment protocol, and can be utilized for identification of biomarkers associated with particular cancers and/or particular anticancer therapies, among other beneficial uses.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: July 14, 2020
    Assignee: University of South Carolina
    Inventors: Vimala Kaza, Eleni Farmaki, Ioulia Chatzistamou, Hippokratis Kiaris
  • Patent number: 10655100
    Abstract: The present invention relates to a method of inducing the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by CXCR2 stimulation, and more particularly, to a method of promoting the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by stimulating and activating the surface receptor CXCR2 of the embryoid bodies with the CXCR2-specific ligand GRO-?. The method of inducing the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by CXCR2 stimulation according to the present invention can increase the efficiency and utility of stem cells as a cell therapeutic agent, because it promotes the differentiation of stem cells into a specific germ layer serving as the origin of target cells, which is the first important step for inducing the differentiation of stem cells into specific cells.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: May 19, 2020
    Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Byung Soo Kim, Ji-Hye Jung, Yong Park
  • Patent number: 10640800
    Abstract: Provided herein is a mouse that produces hybrid antibodies containing human variable regions and mouse constant regions.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: May 5, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn MacDonald, Sean Stevens, Aris N. Economides, David M. Valenzuela
  • Patent number: 10617771
    Abstract: The present invention provides new Adeno-associated virus-derived vectors and pharmaceutical compositions containing the same for the treatment of lysosomal storage disorders and specially, for the treatment of mucopolysaccharidoses Type II.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: April 14, 2020
    Assignees: UNIVERSITAT AUTÓNOMA DE BARCELONA, ESTEVE PHARMACEUTICALS, S.A.
    Inventors: Maria Fàtima Bosch Tubert, Virginia Areba Haurigot, Sandra Motas Mallol
  • Patent number: 10603351
    Abstract: In one aspect, the invention provides methods for preferentially killing target proliferating cells in a host, such as cancer cells, by infecting host tissues with two or more strains of virus. The strains of virus may be selected to provide a synergistic and symbiotic effect, involving a contemporaneous lytic infection in the target proliferating cells. In selected embodiments, the viruses are selected so that expression of a first virulence factor in proliferating cells infected with the first virus increases the lytic effect of the second virus; and, expression of the second virulence factor in proliferating cells infected with the second virus increases the lytic effect of the first virus. The genomes of the first and second viruses may be selected so that they are incompatible for recombination between the viral genomes in cells of the host.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: March 31, 2020
    Assignee: TURNSTONE LIMITED PARTNERSHIP
    Inventors: John C. Bell, Fabrice Le Boeuf
  • Patent number: 10603407
    Abstract: The invention relates to the use of an active collagen matrix for culturing mammalian cells and the use of the active collagen matrix and cells for the treatment of disease.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: March 31, 2020
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Abdulhafez A. Selim, Lawrence A. Shimp, Hsiu Ying Sherry Wang
  • Patent number: 10604738
    Abstract: This invention relates to the forward programming of pluripotent stem cells (PSCs) into megakaryocyte (MK) progenitor cells using the transcription factors GATA1, FLI1 and TAL1. Methods of producing megakaryocyte (MK) progenitor cells and subsequently differentiating them into mature megakaryocytes are provided.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: March 31, 2020
    Assignee: Cambridge Enterprise Limited
    Inventors: Roger Pedersen, Willem Ouwehand, Thomas Moreau, Cedric Ghevaert, Matthew Trotter
  • Patent number: 10590393
    Abstract: In one embodiment, the present invention is a method of creating a fully-human blood-brain barrier (BBB) model, comprising the steps of (a) obtaining a mixture of neural cells and brain microvascular endothelial cells (BMECs), wherein the neural cells and BMECs that comprise the mixture were produced from the differentiation of human pluripotent stem cells (hPSCs); (b) purifying BMECs from the mixture of neural cells and BMECs of step (a); and (c) co-culturing the purified BMECs with a cell type selected from the group consisting of pericytes, astrocytes and differentiated neural progenitor cells (NPCs), wherein a blood brain barrier model is created.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: March 17, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Eric V. Shusta, Sean P. Palecek, Ethan S. Lippmann, Samira M. Azarin
  • Patent number: 10584364
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: March 10, 2020
    Assignee: Rgeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn Macdonald, Sean Stevens, Aris N. Economides, David M. Valenzuela
  • Patent number: 10583200
    Abstract: A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: March 10, 2020
    Assignee: EnGeneIC Molecular Delivery Pty Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 10568974
    Abstract: The present invention provides transgenic, large non-human animal models of atherosclerosis and hypercholesterolemia, as well as methods of using such animal models in the identification and characterization of therapies for atherosclerosis and hypercholesterolemia.
    Type: Grant
    Filed: September 23, 2012
    Date of Patent: February 25, 2020
    Assignee: EXEMPLAR GENETICS LLC
    Inventors: Christopher S Rogers, John R Swart
  • Patent number: 10563191
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 18, 2020
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein